A retrospective study of first‐line therapy and subsequent pyrotinib treatment in advanced lung adenocarcinoma with HER2 mutations

Abstract Objectives HER2 is an infrequently mutated driver gene in non‐small cell lung cancer (NSCLC). At present, there has been no comprehensive large‐scale clinical study to establish the optimal first‐line treatment strategy for advanced lung adenocarcinoma (LUAD) with HER2‐Mutant. Besides that,...

Full description

Bibliographic Details

Published in:	Cancer Medicine
Main Authors:	Li Wang, Yueran Wu, Zhixuan Ren, Xiangling Chu, Jianing Chen, Li Liu, Jing Zhao, Xin Yu, Mengqing Xie, Chunxia Su
Format:	Article
Language:	English
Published:	Wiley 2024-06-01
Subjects:	efficacy first‐line treatment HER2‐mutant lung adenocarcinoma pyrotinib
Online Access:	https://doi.org/10.1002/cam4.7335